Medicinal cannabis in palliative medicine: lessons learnt from randomised controlled trials.
- Publisher:
- BMJ PUBLISHING GROUP
- Publication Type:
- Journal Article
- Citation:
- BMJ Support Palliat Care, 2023, 13, (2), pp. 238-240
- Issue Date:
- 2023-06
Closed Access
Filename | Description | Size | |||
---|---|---|---|---|---|
238.full.pdf | 257.85 kB | Adobe PDF |
Copyright Clearance Process
- Recently Added
- In Progress
- Closed Access
This item is closed access and not available.
Full metadata record
Field | Value | Language |
---|---|---|
dc.contributor.author | Gurgenci, T | |
dc.contributor.author | Hardy, J | |
dc.contributor.author | Olson, R | |
dc.contributor.author | Huggett, G | |
dc.contributor.author | Foster, K | |
dc.contributor.author |
Good, P https://orcid.org/0000-0002-8198-0375 |
|
dc.date.accessioned | 2023-09-11T04:19:25Z | |
dc.date.available | 2022-10-28 | |
dc.date.available | 2023-09-11T04:19:25Z | |
dc.date.issued | 2023-06 | |
dc.identifier.citation | BMJ Support Palliat Care, 2023, 13, (2), pp. 238-240 | |
dc.identifier.issn | 2045-435X | |
dc.identifier.issn | 2045-4368 | |
dc.identifier.uri | http://hdl.handle.net/10453/172032 | |
dc.description.abstract | OBJECTIVES: To detail important lessons learnt while conducting several large, medicinal cannabis (MC) randomised clinical trials in a palliative cancer population. METHODS: Investigators involved in these trials had several meetings to agree on the major lessons learnt and how the various challenges could be mitigated in the future. RESULTS: The lessons were sorted into separate categories: patient confidentiality, family dynamics, driving, cost, unfounded beliefs, accessing specific MC products, trial funding, telehealth and COVID-19, and miscellaneous issues. CONCLUSION: Using MC as the intervention arm in such trials entails some unique regulatory, logistical and other challenges. This short report presents key lessons learnt in conducting these randomised controlled trials in a palliative care population for the benefit of future investigators planning similar trials in a similar patient population. | |
dc.format | Print-Electronic | |
dc.language | eng | |
dc.publisher | BMJ PUBLISHING GROUP | |
dc.relation.ispartof | BMJ Support Palliat Care | |
dc.relation.isbasedon | 10.1136/spcare-2022-004035 | |
dc.rights | info:eu-repo/semantics/closedAccess | |
dc.subject | 1110 Nursing, 1117 Public Health and Health Services | |
dc.subject.classification | 4203 Health services and systems | |
dc.subject.classification | 4205 Nursing | |
dc.subject.mesh | Humans | |
dc.subject.mesh | COVID-19 | |
dc.subject.mesh | Medical Marijuana | |
dc.subject.mesh | Palliative Medicine | |
dc.subject.mesh | Palliative Care | |
dc.subject.mesh | Neoplasms | |
dc.subject.mesh | Randomized Controlled Trials as Topic | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Neoplasms | |
dc.subject.mesh | Palliative Care | |
dc.subject.mesh | Randomized Controlled Trials as Topic | |
dc.subject.mesh | Medical Marijuana | |
dc.subject.mesh | Palliative Medicine | |
dc.subject.mesh | COVID-19 | |
dc.subject.mesh | Humans | |
dc.subject.mesh | COVID-19 | |
dc.subject.mesh | Medical Marijuana | |
dc.subject.mesh | Palliative Medicine | |
dc.subject.mesh | Palliative Care | |
dc.subject.mesh | Neoplasms | |
dc.subject.mesh | Randomized Controlled Trials as Topic | |
dc.title | Medicinal cannabis in palliative medicine: lessons learnt from randomised controlled trials. | |
dc.type | Journal Article | |
utslib.citation.volume | 13 | |
utslib.location.activity | England | |
utslib.for | 1110 Nursing | |
utslib.for | 1117 Public Health and Health Services | |
pubs.organisational-group | /University of Technology Sydney | |
pubs.organisational-group | /University of Technology Sydney/Faculty of Health | |
pubs.organisational-group | /University of Technology Sydney/Faculty of Health/IMPACCT | |
utslib.copyright.status | closed_access | * |
dc.date.updated | 2023-09-11T04:19:24Z | |
pubs.issue | 2 | |
pubs.publication-status | Published | |
pubs.volume | 13 | |
utslib.citation.issue | 2 |
Abstract:
OBJECTIVES: To detail important lessons learnt while conducting several large, medicinal cannabis (MC) randomised clinical trials in a palliative cancer population. METHODS: Investigators involved in these trials had several meetings to agree on the major lessons learnt and how the various challenges could be mitigated in the future. RESULTS: The lessons were sorted into separate categories: patient confidentiality, family dynamics, driving, cost, unfounded beliefs, accessing specific MC products, trial funding, telehealth and COVID-19, and miscellaneous issues. CONCLUSION: Using MC as the intervention arm in such trials entails some unique regulatory, logistical and other challenges. This short report presents key lessons learnt in conducting these randomised controlled trials in a palliative care population for the benefit of future investigators planning similar trials in a similar patient population.
Please use this identifier to cite or link to this item:
Download statistics for the last 12 months
Not enough data to produce graph